ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,710.66
0.09%
Gold vs US Dollar
2,324.535
1.34%
Brent Oil
83.43
0.37%
Bitcoin
63,601.83
-0.62%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Emergent Biosolutions Inc (EBS)

  7. Emergent Biosolutions Inc (EBS) News

Emergent Biosolutions (EBS)

Emergent Biosolutions Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:EBS
DateTimeSourceHeadlineSymbolCompany
01/05/202421:57GlobeNewswire Inc.Emergent BioSolutions Reports First Quarter 2024 Financial ResultsNYSE:EBSEmergent Biosolutions Inc
01/05/202421:10GlobeNewswire Inc.Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial PositionNYSE:EBSEmergent Biosolutions Inc
01/05/202416:03GlobeNewswire Inc.Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to NaloxoneNYSE:EBSEmergent Biosolutions Inc
30/04/202422:26GlobeNewswire Inc.Emergent BioSolutions Announces Amendment to its Existing Credit FacilityNYSE:EBSEmergent Biosolutions Inc
22/04/202413:05GlobeNewswire Inc.Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024NYSE:EBSEmergent Biosolutions Inc
01/04/202413:00GlobeNewswire Inc.Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech ExecutiveNYSE:EBSEmergent Biosolutions Inc
28/03/202412:15GlobeNewswire Inc.Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid CrisisNYSE:EBSEmergent Biosolutions Inc
25/03/202412:05GlobeNewswire Inc.Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing FacilityNYSE:EBSEmergent Biosolutions Inc
08/03/202421:21Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:EBSEmergent Biosolutions Inc
08/03/202401:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
06/03/202421:31GlobeNewswire Inc.Emergent BioSolutions Reports Fourth Quarter 2023 Financial ResultsNYSE:EBSEmergent Biosolutions Inc
06/03/202421:15Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
06/03/202411:02IH Market NewsU.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices ClimbNYSE:EBSEmergent Biosolutions Inc
04/03/202423:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
04/03/202423:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
04/03/202423:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
29/02/202412:00GlobeNewswire Inc.Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024NYSE:EBSEmergent Biosolutions Inc
28/02/202401:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
28/02/202401:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
21/02/202412:25Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
21/02/202412:00GlobeNewswire Inc.Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEONYSE:EBSEmergent Biosolutions Inc
11/01/202412:41Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
09/01/202413:40Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
09/01/202412:30GlobeNewswire Inc.Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024NYSE:EBSEmergent Biosolutions Inc
27/12/202311:08IH Market NewsWall Street Highlights: Apple Appeals Watch Ban, Tesla to Launch Updated Model Y, and MoreNYSE:EBSEmergent Biosolutions Inc
11/12/202322:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:EBSEmergent Biosolutions Inc
11/12/202312:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:EBSEmergent Biosolutions Inc
28/11/202312:15Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
28/11/202311:59GlobeNewswire Inc.Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)NYSE:EBSEmergent Biosolutions Inc
24/11/202312:30GlobeNewswire Inc.Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q FilingNYSE:EBSEmergent Biosolutions Inc
 Showing the most relevant articles for your search:NYSE:EBS

Your Recent History

LSE
POS
Plexus
LSE
RR.
Rolls-royce
LSE
SCE
Surface Transforms
LSE
SRSP
Sirius Petroleum
LSE
BIRD
Blackbird
LSE
HUM
Hummingbird Resources
LSE
SBTX
Skinbiotherapeutics
LSE
AGL
Angle
LSE
AAU
Ariana Resources
LSE
LLOY
Lloyds Banking
LSE
ENET
Ethernity Networks
LSE
SOLG
Solgold
LSE
CHLL
Chill Brands
LSE
ASC
Asos
LSE
BARC
Barclays
LSE
GKP
Gulf Keystone Petroleum
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved